Gedeon Richter shells out $196 million for Swiss women's fertility firm Finox
Hungary’s largest drugmaker Gedeon Richter (RICHT: HB) says it has acquired Finox Holding, a privately held Swiss biotech company focused on development and commercialization of innovative and cost effective products addressing female fertility.
The purchase price for the shares in Finox amounts to 190 million Swiss francs (~$196 million).
Finox' product, Bemfola is a recombinant-human follicle stimulating hormone (r-hFSH) which was developed as a biosimilar to Gonal-f, an established reference product from Germany’s Merck KGaA (MRK: DE). Bemfolawas the first biosimilar r-hFSH launched in Europe. It is currently commercialized in the European Union, in Israel, in the Middle East and in Australia. The product gained significant market share since its initial introduction in second-quarter 2014.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze